ondansetron has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 7 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 6.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| "We performed a clinical study of a triple-drug combination to evaluate its efficacy to prevent both acute and delayed emesis after high-dose chemotherapy with BEAM (BCNU [carmustine]+etoposide+ARA-C [cytarabine]+melphalan) before hematopoietic stem cell transplantation (HSCT) by comparison with a historical control group of patients treated with dexamethasone (dex) and ondansetron or palonosetron." | 5.15 | A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. ( Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A, 2011) |
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 2.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| "Ondansetron or droperidol was given intravenously, 30 min prior to the first dose of IL-2 and then every 8 h for the duration of IL-2 treatment." | 2.67 | A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. ( Cole, DJ; Kim, H; Rosenberg, SA; Steinberg, SM; Weber, JS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, Z | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Zhao, K | 1 |
| Zhang, M | 1 |
| Yang, F | 1 |
| Pielichowski, W | 1 |
| Barzal, J | 1 |
| Gawronski, K | 1 |
| Mlot, B | 1 |
| Oborska, S | 1 |
| Wasko-Grabowska, A | 1 |
| Rzepecki, P | 1 |
| Colquhoun, JP | 1 |
| Kim, H | 1 |
| Rosenberg, SA | 1 |
| Steinberg, SM | 1 |
| Cole, DJ | 1 |
| Weber, JS | 1 |
| Fedele, P | 1 |
| Spina, M | 1 |
| Valentini, M | 1 |
| Collini, D | 1 |
| Lucia, C | 1 |
| Manicone, M | 1 |
| Tirelli, U | 1 |
| Wong, ET | 1 |
| Portlock, CS | 1 |
| O'Brien, JP | 1 |
| DeAngelis, LM | 1 |
| Gibbs, SJ | 1 |
| Cassoni, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for ondansetron and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug | 2017 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex | 2011 |
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Topics: Adult; Aged; Carcinoma, Renal Cell; Droperidol; Female; Humans; Interleukin-2; Lymphoma, Non-Hodgkin | 1994 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Granisetron; Humans; Lymphoma, AIDS-Related; Lympho | 1995 |
Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dox | 1996 |
A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation.
Topics: Administration, Oral; Antiemetics; Bone Marrow Transplantation; Cost-Benefit Analysis; Drug Administ | 1996 |
1 other study available for ondansetron and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
The mark of Zorro.
Topics: Acyclovir; Aged; Anecdotes as Topic; Family Practice; Female; Herpes Zoster Oticus; Humans; Leukemia | 1994 |